Adaptive Biotechnologies (NASDAQ:ADPT) CEO Chad Robins Sells 83,332 Shares

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) CEO Chad Robins sold 83,332 shares of the company’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $14.41, for a total value of $1,200,814.12. Following the completion of the sale, the chief executive officer owned 2,217,781 shares in the company, valued at $31,958,224.21. This represents a 3.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Stock Up 8.2%

Shares of NASDAQ:ADPT opened at $14.84 on Thursday. Adaptive Biotechnologies Corporation has a 52-week low of $6.77 and a 52-week high of $20.76. The stock’s fifty day simple moving average is $15.17 and its 200-day simple moving average is $15.98. The company has a market capitalization of $2.29 billion, a P/E ratio of -37.10 and a beta of 2.29.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.10. Adaptive Biotechnologies had a negative return on equity of 46.68% and a negative net margin of 21.48%.The business had revenue of $71.68 million for the quarter, compared to the consensus estimate of $59.38 million. During the same period in the prior year, the business earned ($0.23) earnings per share. The business’s revenue was up 51.0% on a year-over-year basis. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Analysts Set New Price Targets

Several brokerages have recently issued reports on ADPT. Weiss Ratings restated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research report on Wednesday, January 21st. JPMorgan Chase & Co. increased their target price on Adaptive Biotechnologies from $20.00 to $21.00 and gave the stock an “overweight” rating in a research report on Friday, February 6th. Wall Street Zen downgraded Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research report on Friday, February 6th. Finally, TD Cowen reiterated a “buy” rating on shares of Adaptive Biotechnologies in a research report on Friday, February 6th. Seven research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Trending Headlines about Adaptive Biotechnologies

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: AAII highlights a sharp intraday rally in ADPT and links the move to the company’s recent quarter-to-quarter momentum, citing earlier-quarter beats in revenue and EPS and strong year-over-year revenue growth as the core catalyst. Why Adaptive Biotechnologies Corporation’s (ADPT) Stock Is Up 10.28%
• Positive Sentiment: The Motley Fool coverage notes revenue jumped roughly mid‑50% year-over-year in the most recent period, a headline that supports the bullish narrative on growth and may be driving buying interest; the piece also flags areas investors should watch (guidance, margins, product adoption). Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%
• Neutral Sentiment: Executives disclosed that many of the recent stock sales were executed under pre‑arranged Rule 10b5‑1 trading plans, which can reduce concerns of opportunistic timing but still represent share supply hitting the market. SEC Form 4 (Example)
• Negative Sentiment: Multiple insider sales by top executives may weigh on sentiment — CEO Chad M. Robins sold blocks on Apr. 6 and Apr. 8 (about 120,595 shares across those filings at prices ~ $14.41–$15.19), and COO Julie Rubinstein sold multiple blocks in early April (roughly 88,000 shares across filings, with trade prices from ~$13.56–$14.83). These transactions reduced each executive’s direct holdings by a few percent. CEO Form 4 COO Form 4

Hedge Funds Weigh In On Adaptive Biotechnologies

Several large investors have recently added to or reduced their stakes in ADPT. AQR Capital Management LLC lifted its position in Adaptive Biotechnologies by 45.8% during the first quarter. AQR Capital Management LLC now owns 310,272 shares of the company’s stock worth $2,265,000 after buying an additional 97,444 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Adaptive Biotechnologies by 4.4% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 68,830 shares of the company’s stock worth $511,000 after acquiring an additional 2,914 shares during the last quarter. Caxton Associates LLP acquired a new stake in Adaptive Biotechnologies during the first quarter worth about $93,000. Rhumbline Advisers increased its stake in Adaptive Biotechnologies by 11.4% during the second quarter. Rhumbline Advisers now owns 210,001 shares of the company’s stock worth $2,447,000 after acquiring an additional 21,477 shares during the last quarter. Finally, New York State Common Retirement Fund increased its stake in Adaptive Biotechnologies by 39.2% during the second quarter. New York State Common Retirement Fund now owns 47,258 shares of the company’s stock worth $551,000 after acquiring an additional 13,300 shares during the last quarter. 99.17% of the stock is currently owned by hedge funds and other institutional investors.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.